This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Golcadomide
- DrugBank Accession Number
- DB18115
- Background
Not Available
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Golcadomide (DB18115)
- Weight
- Average: 535.576
Monoisotopic: 535.223097249 - Chemical Formula
- C28H30FN5O5
- Synonyms
- 2-[(3S)-2,6-dioxopiperidin-3-yl]-4-{[(2-fluoro-4-{[3-(morpholin-4-yl)azetidin-1-yl]methyl} phenyl) methyl]amino}-1H-isoindole-1,3(2H)-dione
- External IDs
- CC 99282
- CC-99282
- CC99282
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Golcadomide hydrochloride 488383336A 2639939-36-7 Not applicable
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 29HLR8Z5BR
- CAS number
- 2379572-34-4
- InChI Key
- NZYDBVQXOGPDDU-QHCPKHFHSA-N
- InChI
- InChI=1S/C28H30FN5O5/c29-21-12-17(14-32-15-19(16-32)33-8-10-39-11-9-33)4-5-18(21)13-30-22-3-1-2-20-25(22)28(38)34(27(20)37)23-6-7-24(35)31-26(23)36/h1-5,12,19,23,30H,6-11,13-16H2,(H,31,35,36)/t23-/m0/s1
- IUPAC Name
- 2-[(3S)-2,6-dioxopiperidin-3-yl]-4-{[(2-fluoro-4-{[3-(morpholin-4-yl)azetidin-1-yl]methyl}phenyl)methyl]amino}-2,3-dihydro-1H-isoindole-1,3-dione
- SMILES
- FC1=CC(CN2CC(C2)N2CCOCC2)=CC=C1CNC1=CC=CC2=C1C(=O)N([C@H]1CCC(=O)NC1=O)C2=O
References
- General References
- Not Available
- External Links
- ChemSpider
- 115010586
- ChEMBL
- CHEMBL5095226
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data3 Recruiting Treatment Large B Cell Lymphoma 1 somestatus stop reason just information to hide 2 Recruiting Treatment Follicular Lymphoma ( FL) 1 somestatus stop reason just information to hide 2 Recruiting Treatment Follicular Lymphoma ( FL) / Tumor 1 somestatus stop reason just information to hide 2 Recruiting Treatment Non-Hodgkin's Lymphoma (NHL) 1 somestatus stop reason just information to hide 2 Recruiting Treatment Refractory Diffuse Large B Cell Lymphoma (DLBCL) / Refractory High Grade B-cell Lymphoma (HGBCL) / Refractory Primary Mediastinal Large B-Cell Cell Lymphoma / Refractory Transformed B-cell Non-Hodgkin Lymphoma 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP 1.64 Chemaxon pKa (Strongest Acidic) 11.59 Chemaxon pKa (Strongest Basic) 6.51 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 8 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 111.29 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 142.69 m3·mol-1 Chemaxon Polarizability 55.54 Å3 Chemaxon Number of Rings 6 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at September 12, 2023 16:43 / Updated at September 28, 2023 05:48